| abstract |
A method and composition that can reduce the frequency of adverse effects associated with the use of adjuvants in vaccines. A method for generating an antibody titer associated with administration of an antigen to a subject, the method comprising providing a dose of an adjuvant and a dose of the antigen; Generating an antibody titer against the antigen by administering to the subject a different dose of the same titer as that produced by administering the dose of the adjuvant and the dose of the antigen to the subject. Selecting a dose of the adjuvant to be less than the adjuvant, wherein an adjuvant corresponding to at least a portion of the dose is bound to the synthetic nanocarrier. Preferably, the adjuvant is a Toll-like receptor agonist such as R848 (resiquimod). The synthetic nanocarrier is preferably a polyester such as PLA (polylactic acid). Preferably, said antigen is nicotine. [Selection diagram] None |